JORDAN VAUGHN, M.D.

CAHABA RESEARCH, INC.

Division of MedHelp Clinics

Phone 205.408.4134

Fax 205.263.2315

Email: jvaughn@cahabaresearch.com

Website: www.medhelpclinics.com

www.cahabaresearch.com

CLINIC ADDRESS:

Cahaba Research, Inc.
4600 Highway 280
Birmingham, AL 35242

Cahaba Research, Inc.
One West Lakeshore Drive, Suite 100
Birmingham, AL 35209

Cahaba Research, Inc.
5915 Chalkville Mountain Road, Suite 100
Birmingham, AL 35235

Cahaba Research, Inc.
3143 Pelham Parkway, Suite 100
Pelham, AL 35124

Cahaba Research, Inc.
151 Narrows Parkway
Birmingham, AL 35242

EDUCATION:

University of Alabama Hospital, Birmingham, Alabama
Internal Medicine Residency
2009 to 2012

University of Alabama School of Medicine Birmingham, Alabama
Doctor of Medicine
2005 to 2009

University of Alabama, Tuscaloosa, Alabama
Bachelor of Science in Chemical and Biological Engineering
2001 to 2005

PROFESSIONAL EXPERIENCE:

Cahaba Research, Inc.
Birmingham, AL
Sub Investigator and/or Principal Investigator
2012 to Present

MedHelp Clinics
Birmingham, AL
Primary Care Physician
2012 to Present

LICENSE AND BOARD CERTIFICATIONS:

- Alabama Medical License #30484
- DEA Certificate
- Board Certified Internal Medicine (ABIM)

CLINICAL RESEARCH EXPERIENCE:

1. A Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess the Analgesic Efficacy (Compared to Placebo) and the Management of Opioid-induced Constipation (Compared to Oxycodone Controlled-release Tablets (OXY)) in Opioid-experienced Subjects with Uncontrolled Moderate to Severe **Chronic Low Back Pain** and a History of **Opioid-induced Constipation** who Require Around-the-clock Opioid Therapy.

2. Sanofi Pasteur CYD51: Evaluation of the Immune Response to Different Schedules of a Tetravalent **Dengue Vaccine** Administered With or Without Yellow Fever Vaccine in US Adults.

3. A randomized, observer-blind, active-controlled phase III study to demonstrate the superior efficacy of GSK Biologicals' adjuvanted **influenza candidate vaccine** [GSK2186877A], administered intramuscularly in elderly aged 65 years or above, as compared to Fluarix™.

4. A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Two Doses of Favipiravir in Adult Patients with **Uncomplicated Influenza (US317)**.

5. A Randomized,12-Week, Double-Blind, Placebo Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients with **Chronic Idiopathic Constipation (CIC)**.

6. An Open-Label Extension (OLE), Long-Term Safety and Tolerability Study of Plecanatide in Patients with **Chronic Idiopathic Constipation (CIC)**.

7. A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Favipiravir in Adult Subjects with **Uncomplicated Influenza (US317)**.

CLINICAL RESEARCH EXPERIENCE (Con't):

8. A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Favipiravir in Adult Subjects with **Uncomplicated Influenza (US316)**.

9. IQIV-ID Immunogenicity and Safety Trial of Quadrivalent **Influenza Vaccine** Administered by Intradermal Route in Adult Subjects Aged 18 through 64 Years.

10. A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of 2 Dose Levels of VX-787 Administered as Monotherapy and One Dose Level of VX-787 Administered in Combination With Oseltamivir for the Treatment of Acute **Uncomplicated Seasonal Influenza A** in Adult Subjects.

11. Clinical Evaluation of an Improved BinaxNOW **Influenza** A&B Card.

12. A Randomized, Double-Blind, Placebo-And Active-Controlled Study of DS-5565 In Subjects With Pain Associated With **Fibromyalgia**.

13. An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With **Fibromyalgia**.

14. An Efficacy and Safety Study of Sustained-release Paracetamol in Subjects with **Osteoarthritis**.

15. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women with **Hypoactive Sexual Desire Disorder (HSDD)** with or without Decreased Arousal.

16. A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Plecanatide in Patients with **Irritable Bowel Syndrome with Constipation (IBS-C)**.

17. A Multicenter, Randomized, Double-Blind, Parallel-Group, Comparative Study of FV-100 vs. Valacyclovir for the Prevention of **Post-Herpetic Neuralgia** and Treatment of **Acute Herpes Zoster-Associated Pain**.

18. Clinical Evaluation of the Alere™ BinaxNOW **Influenza** A&B Card Assay and Alere™ Reader.

19. Evaluation of the Clinical Performance of the Alere™ i **RSV** Test.

20. A Prospective Non-Interventional Registry Study of Patients Initiating a Course of Drug Therapy for **Overactive Bladder (OAB)** PERSPECTIVE.

21. A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study with a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of **Constipation-Predominant Irritable Bowel Syndrome (IBS-C)**.

CLINICAL RESEARCH EXPERIENCE (Con't):

22. A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF A DOSE TITRATION REGIMEN FOR THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH **OSTEOARTHRITIS OF THE HIP OR KNEE**.

23. A PHASE 3, MULTICENTER, LONG-TERM OBSERVATIONAL STUDY OF SUBJECTS FROM TANEZUMAB STUDIES WHO UNDERGO A **TOTAL KNEE, HIP OR SHOULDER REPLACEMENT**.

24. A Phase 3, Randomized, Double Blind, Placebo and Active-Controlled, Multicenter, Parallel-Group Study of the Analgesic Efficacy and Safety of Tanezumab in Adult Patients with **Chronic Low Back Pain**.

25. An Exploratory, Randomized, Double-Blind, Crossover Study to Compare the Efficacy and Safety of BIIB074 Versus Placebo in the Treatment of **Primary Inherited Erythromelalgia.**

26. A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared with Placebo or Oseltamivir 75mg Twice Daily for 5 Days in Patients with **Influenza** at High-Risk of Influenza Complications (CAPSTONE-2).

27. A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared with Placebo or Oseltamivir 75mg Twice Daily for 5 Days in Otherwise Healthy Patients with **Influenza** (CAPSTONE-1).

28. Evaluation of the Clinical Performance of the modified Alere™ I **Influenza** A&B Test.

29. Throat Swab Collection for the Detection of **Group A Streptococcus**.

30. Clinical Evaluation of the Alere™ BinaxNOW **Influenza** A&B Card 2 Assay and the Alere™ Reader with Viral Transport Media (VTM).

31. Throat and Nasopharyngeal Swab Specimen Collection for Detection of **Mycoplasma pneumoniae** and **Chlamydia pneumoniae** Organisms in Subjects with **Respiratory Tract Infections**.

32. A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Assess the Efficacy and Safety of Ciprofloxacin 0.3% plus Fluocinolone acetonide 0.025% Otic Solution Compared to Ciprofloxacin 0.3% Otic Solution and to Fluocinolone acetonide 0.025% Otic Solution in the Treatment of **Acute Otitis Externa (AOE)**.

33. A Randomized, Double-blind, Placebo-controlled, Single Injection, 52-Week Study to Evaluate the Efficacy and Safety of an Intra-articular Injection of CNTX-4975-05 in Subjects with Chronic, Moderate-to-Severe **Osteoarthritis Knee Pain**.

34. A Phase 3, Randomized, Double Blind, Placebo Controlled Study to Evaluate Bexagliflozin in Subjects with **Type 2 Diabetes Mellitus** who are not Adequately Controlled by Metformin Alone (Bexa-Met).

CLINICAL RESEARCH EXPERIENCE (Con't):

35. A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With a 40-Week, Active-Controlled, Double-Blind Extension to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting **Triglyceride** Levels ≥ 500 mg/dL and < 2000 mg/dL and Normal Renal Function.

36. Evaluation of the Clinical Performance of the Alere™ **Influenza** A&B Test.

37. REAL-WORLD PERCEPTION OF TOLERABILITY AND BOWEL FUNCTION EFFECTS OF FUCO-N-TETRAOSE IN **IBS** PATIENTS.

38. A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Non-hospitalized Subjects With **Influenza A Infection** who Are at Risk of Developing Complications.

39. A Phase 4, randomized, double-blind, placebo-controlled, multicenter study of topical testosterone replacement therapy (TRT) in symptomatic **hypogonadal men** with increased risk for **cardiovascular (CV) disease**.

40. A prospective, Phase 3, randomized, multi-center, double-blind study of the efficacy, tolerability, and safety of oral sulopenem etzadroxil/probenecid versus oral ciprofloxacin for treatment of **uncomplicated urinary tract infections** in adult women.

41. A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF NITAZOXANIDE IN THE TREATMENT OF COLDS DUE TO ***ENTEROVIRUS/RHINOVIRUS*** **INFECTION**.

42. Collection of Nasopharyngeal and Nasal Swabs for use in Development of **Rapid Diagnostic Tests** for **Influenza A&B and RSV**. (Protocol 1825301)

43. Evaluation of the Clinical Performance of the modified Alere™ **Influenza A & B** Test. (Protocol 1822001)

44. A multi-center, randomized, double-blind, and placebo-controlled phase II clinical study to investigate the safety and efficacy of two doses of KT07 compared to placebo in subjects with **acute uncomplicated influenza**. (Protocol KT07-US-01)

45. A Multicenter Study Conducted to Evaluate the Performance of the Theraflu Home **Flu Test**. (Protocol CS-ELMFLU18-01)

46. A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the **Treatment of Uncomplicated Influenza**. (Protocol RM08-3004)

CLINICAL RESEARCH EXPERIENCE (Con't):

47. A Multicenter Study to Evaluate the Performance of the Diassess **Influenza A & B Test** in Point-of-Care Testing Sites. (Protocol 04A-CLI-002)

48. A Multicenter Study Conducted to Evaluate the Performance of the Mesa Biotech Accula™ **Strep A Test** in Point of Care Locations. (Protocol CS-MESSTR18-01)

49. A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients with **Type 2 Diabetes** (SURPASS-2). (Protocol 18F-MC-GPGL)

50. A PHASE 2B DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF NORKETOTIFEN IN THE TREATMENT OF ACUTE UNCOMPLICATED **INFLUENZA-LIKE ILLNESS** (ILI). (Protocol NKT-202)

51. A PHASE IIIB, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL EFFICACY STUDY OF BALOXAVIR MARBOXIL FOR THE REDUCTION OF DIRECT TRANSMISSION OF **INFLUENZA** FROM OTHERWISE HEALTHY PATIENTS TO HOUSEHOLD CONTACTS. (Protocol MV40618)

52. Efficacy and Safety of Tirzepatide Once Weekly in Participants without Type 2 Diabetes Who Have **Obesity** or are Overweight with Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1). (Protocol I8F-MC-GPHK)

53. A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF EDP-938 ADMINISTERED ORALLY FOR THE TREATMENT OF ACUTE UPPER RESPIRATORY TRACT INFECTION WITH **RESPIRATORY SYNCYTIAL VIRUS** IN AMBULATORY ADULT SUBJECTS (RSVP). (Protocol EDP-938-102)

54. A Multicenter Study Conducted to Evaluate the Performance of the LumiraDx **Influenza A/B + RSV Test** at Point of Care Testing Sites. (Protocol CS-LUMFLU19-01)

55. A Multicenter Study Conducted to Evaluate the Performance of the Theraflu **fluTEST** Home Diagnostic Kit. (Protocol CS-ELMFLU20-01)

56. A Multicenter Study Conducted to Evaluate the Performance of the pinch **COVID-19** Testing System as Compared to an EUA PCR Test. (Protocol CS-1214-01)

57. A Multicenter Study Conducted to Evaluate the Performance of the VitaPCR™ **Flu A&B** Assay at Point of Care Testing Sites. (Protocol CS-1223-01)

58. A Multicenter Study Conducted to Evaluate the Performance of the **COVID-19** Home Test Protocol#: CS-1233-01

59. BinaxNOW™ **COVID-19** Ag Card: Clinical Evaluation to Support Prescription Home Use via Telehealth. Protocol#: 2029301

CLINICAL RESEARCH EXPERIENCE (Con't):

60. PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TRIAL TO EVALUATE EFFICACY AND SAFETY OF NITAZOXANIDE IN THE TREATMENT OF **MILD OR MODERATE COVID-19**. (Protocol RM08-3008)

61. PHASE 3, RAMDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF NITAZOXANIDE IN THE TREATMENT OF **COLDS DUE TO ENTEROVIRUS/RHINOVIRUS INFECTION**. (Protocol RMO8-3009)

62. A Multicenter Study Conducted to Evaluate the Performance of the **COVID-19** Self-Test. Protocol CS-1251-01

63. A Multicenter Study Conducted to Evaluate the Performance of the BD Veritor™ At-Home **COVID-19** Test. (Protocol CS-1276-01)

64. Efficacy and Safety of Tirzepatide Once Weekly versus Placebo for Maintenance of **Weightloss** in Participants without Type 2 Diabetes Who Have **Obesity** or are Overweight with Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4). (Protocol 18F-MC-GPHN)

65. FAVIPIRAVIR in COVID-19, Effect on viral shedding and disease progression. The **Pre**vent **Se**vere **CO**VID-19 (PRESECO) Study. (Protocol ATI0220)

66. A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRX, an Antisense Inhibitor of Angiotensinogen Production Administered Subcutaneously for 12 Weeks to Hypertensive Patients with **Uncontrolled Blood Pressure**. (Protocol ISIS 757456-CS4)

67. QuickVue At-Home **COVID-19** Validation Study. (Protocol CS-0164-01)

68. Sofia 2 **SARS+** Validation Study. (Protocol CS-0290-01)

69. A Multicenter Study Conducted to Evaluate the Performance of the Omnia™ **SARS-CoV-2** Antigen Test in Point of Care Locations. (Protocol CS-6198-01)

70. A Multicenter Study Conducted to Evaluate the Performance of the Veros™ **COVID-19** Test. (Protocol CS-1282-01)

71. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 **Cytomegalovirus (CMV) Vaccine** in Healthy Females 16-40 Years of Age. (Protocol mRNA-1647-P301)

72. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of GS500 in Subjects with **Functional Constipation**. (Protocol GS-500-001)

CLINICAL RESEARCH EXPERIENCE (Con't):

73. A Multicenter Study Conducted to Evaluate the Performance of the AMIRA **COVID-19** Self-Test. (Protocol CS-1279-01)

74. A Multicenter Study Conducted to Evaluate the LumiraDx **SARS-CoV-2 Ab Test** Results following COVID-19 Vaccination. (Protocol CS-1306-01)

75. AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH **COVID-19** WHO ARE AT LOW-RISK OF PROGRESSING TO SEVERE ILLNESS. (Protocol C4671002)

76. AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH **COVID-19** WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS. (Protocol C4671005)

77. A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332/RITONAVIR IN PREVENTING SYMPTOMATIC **SARS-COV-2 INFECTION** IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID-19. (Protocol C4671006)

78. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of **COVID-19** (Laboratory-confirmed SARS-CoV-2 Infection with Symptoms) in Adults Residing With a Person with COVID-19. (Protocol 013-01)

79. VITROS IMMUNODIAGNOSTIC PRODUCTS **SARS-COV-2** ANTIGEN SPECIMEN COLLECTION PROTOCOL. (Protocol D53884)

80. A PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, 22-WEEK AND 30-WEEK OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF X0002 SPRAY IN RELIEF OF THE PAIN FOR SUBJECTS WITH **OSTEOARTHRITIS OF THE KNEE**. (Protocol TF-X0002-31)

81. Clinical Study of the Cue® **Influenza Test** with Lay Users Self-Testing in a Simulated Home Use Setting. (Protocol CP-INFLU-001)

82. A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared with Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of **Type 2 Diabetes**. (SURPASS-EARLY) (Protocol 18F-MC-GPHE)

83. A Multicenter Study Conducted to Evaluate the Performance of the Advin **COVID-19 Antigen Test** @ Home. (Protocol CS-1366-01)

84. A Multicenter COVID-19 Study Conducted to Evaluate the Performance of the LumiraDx **SARS-CoV-2 Ag Ultra Test** at Point of Care Testing Sites. (Protocol CS-1357-01)

CLINICAL RESEARCH EXPERIENCE (Con't):

85. Clinical Evaluation of the BinaxNOW™ **COVID-19 Ag / Flu A & B Combo Card** Using Retrospective Samples and Samples at the Limit of Detection (LOD). (Protocol 2128501)

86. A Multicenter Study Conducted to Evaluate the Clinical Performance of the Ellume **COVID-19 Home Test** in Symptomatic Individuals. (Protocol CS-1395-01)

87. QuickVue ABC Validation Study. (Protocol CS-0172-01)

88. PerkinElmer/"Post EUA Evaluation of PKamp™ Respiratory **SARS CoV-2** RT-PCR Panel 1. (Protocol R01-210105)

89. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effects of EDP-235 in Non-hospitalized Adults with **Mild or Moderate COVID-19**. (Protocol EDP-235-101)

90. A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 Administered Weekly Using a Fixed Dose Escalation Compared to Insulin Glargine in Insulin-Naïve Adults with **Type 2 Diabetes**. (Protocol 18F-MC-BDCW)

91. Clinical Validation of the Mologic Inc COVI-Go™ **SARS-CoV-2 Ag Self-Test** in anterior nares nasal samples For Over-The-Counter (OTC) Use. (Protocol 7697-2022)

92. A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 mg in Adults Who Have **Obesity or Overweight** with Weight-Related Comorbidities (SURMOUNT-5) (Protocol 18F-MC-GPHJ)

93. A Multicenter Study Conducted to Evaluate the Performance of Veros™ **COVID-19** (US) as a Point-of-Care SARS-CoV-2 Diagnostic. (Protocol CS-1423-01)

94. Clinical Evaluation of the BinaxNOW™ **COVID-19 Ag / Flu A & B Combo Card**. (Protocol 2218801)

95. Clinical Evaluation of The BD Veritor™ **COVID-19 & Flu Home Test**. (Protocol CS-1435-01)

96. Sofia 2 RVP4 Validation Study with New Cassette Format. (Protocol CS-0274-07)

97. Human Factors and Clinical Validation of the Princeton BioMeditech Corp. Over-the-Counter (OTC) *Status™* **COVID-19 Antigen Test** in anterior nares nasal samples For Over-The-Counter (OTC) Use. (Protocol 13356B)

98. A Phase 3, Open-Label Study of Once Daily LY3502970 Compared with Insulin Glargine in Adult Participants with **Type 2 Diabetes** and **Obesity or Overweight** at Increased Cardiovascular Risk (ACHIEVE-4) (Protocol J2A-MC-GZGS)

CLINICAL RESEARCH EXPERIENCE (Con't):

99. A Clinical Study Conducted to Evaluate the Performance of the CareSuperb™ **COVID-19/Flu A&B Antigen Combo Home Test**. (Protocol CS-1466-01)

100. Clinical Investigation for WELLlife™ **Influenza A&B Test** POC for 510(k) Submission & CLIA Waiver by Application. (Protocol CS-1467-01)

101. A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared with Placebo in Adult Participants with **Obesity or Overweight** and **Type 2 Diabetes** (ATTAIN-2) (Protocol J2A-MC-GZGQ)

102. Human Factors and Clinical Validation of the Heal-Check Rapid **COVID-19 Antigen Self-Test** in Anterior Nares Nasal Samples for Over-the-Counter (OTC) Use. (Protocol PR22-011)

103. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 for the **Treatment of COVID-19** in Nonhospitalized Participants. (Protocol GS-US-611-6549)

104. A Clinical Study Conducted to Evaluate the Performance of the CareSuperb™ **COVID-19 Antigen Home Test**. (Protocol CS-1498-01)

105. Savanna RVP4 Validation Study. (Protocol CS-0605-03)

_____ / _____
Jordan Vaughn, M.D. **15 JUN 2023**